Search Result

Pathways Recommended:	PROTAC

Results for "

ALK PROTAC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (10) PROTAC Linkers (3) Apoptosis (4) c-Met/HGFR (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (2) FKBP (1) PROTACs (13) ROS Kinase (1)
By Research Areas:	Cancer (17)
Click Chemistry:	PROTAC Synthesis (2) Azide (1) Alkynes (2)

Inhibitors & Agonists

Click Chemistry

Targets Recommended: PROTAC Linkers Anaplastic lymphoma kinase (ALK) PROTAC-Linker Conjugates for PAC Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122582

TL13-12	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-12 is a potent and selective?ALK-PROTAC?degrader and inhibits?ALK?activity with an IC₅₀ value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC₅₀ values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .

HY-112156

MS4077	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
MS4077 is an anaplastic lymphoma kinase (ALK) *PROTAC* (degrader) based on Cereblon ligand, with a K_d of 37?nM for binding affinity to ALK .

HY-112155

MS4078 1 Publications Verification	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
MS4078 is an anaplastic lymphoma kinase (ALK) *PROTAC* (degrader) based on Cereblon ligand, with a K_d of 19?nM for binding affinity to ALK .

HY-168551

PROTAC ALK degrader-3	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
PROTAC ALK degrader-3 (4B) is an orally active *ALK* degrader based on PROTACs, which can effectively induce persistent degradation of ALK fusion protein in Karpas 299 cells and strong inhibition of downstream pathways,IC₅₀ is 119.33 nM. PROTAC ALK degrader-3 exhibits antitumor activity. (Srtucture Note: PINK, ALK Inhibitor (HY-15656); Blue, E3 (HY-W023573); Black, linker (HY-168552l)) .

HY-161749

PROTAC ALK degrader-1	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
PROTAC ALK degrader-1 (compound B1) is an *ALK* degrader based on *PROTACs, with the DC₅₀* of 26 nM in H3122 EML4-ALK. PROTAC ALK degrader-1 can be used to synthesis PROTAC ALK degrader-2 (HY-161750) with superior bioavailability .

HY-161750

PROTAC ALK degrader-2	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
PROTAC ALK degrader-2 (B1-PEG) is an *ALK* degrader based on *PROTACs, with the DC₅₀* of 45 nM in H3122 EML4-ALK DC50 (GSH+). PROTAC ALK degrader-2, through PEGylation, is engineered to self-organize into micelles in water and releases its active form in response to the tumor-specific high GSH environment .

HY-168552

3-Hydroxyazetidine-Cyclohexanol	PROTAC Linkers	Cancer
3-Hydroxyazetidine-Cyclohexanol is a PROTAC linker that can be used in the synthesis of ALK PROTAC (HY-168551) .

HY-168553

3-Hydroxyazetidine-Cyclohexanol-5-Aminothalidomide	E3 Ligase Ligand-Linker Conjugates	Cancer
3-Hydroxyazetidine-Cyclohexanol-5-Aminothalidomide is a E3 ligase ligand-linker conjugate that can be used in the synthesis of ALK PROTAC (HY-168551) .

HY-147206D

Biotin-PEG-Alk (MW 5000)	PROTAC Linkers	Cancer
Biotin-PEG-Alk (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Biotin-PEG-Alk (MW 5000) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147219

SIAIS164018	PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis	Cancer
SIAIS164018 is a *PROTAC*-based *ALK* and EGFR degrader, with IC₅₀ value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 exhibits better property than Brigatinib (HY-12857) .

HY-147219A

SIAIS164018 hydrochloride	PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis	Cancer
SIAIS164018 hydrochloride is a *PROTAC*-based *ALK* and EGFR degrader, with IC₅₀ value of 2.5 nM and 6.6 nM for ALK and ALK G1202R, respectively. SIAIS164018 hydrochloride strongly inhibits cancer cells migration and invasion, causes G1 cell cycle arrest and induces apoptosis. SIAIS164018 hydrochloride exhibits better property than Brigatinib (HY-12857) .

HY-146022

SIAIS117	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
SIAIS117 is a potent *Brigatinib-PROTAC* degrader. SIAIS117 is a **ALK PROTAC** based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade ALK G1202R point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines. SIAIS117 has the potentially anti-proliferation ability of small cell lung cancer .

HY-W040304

Alkynyl Palmitic Acid 1 Publications Verification ALK-C16	PROTAC Linkers	Cancer
Alkynyl Palmitic Acid (Alk-C16) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs . Alkynyl Palmitic Acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-123919

TL13-112 1 Publications Verification	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-112 is a potent and selective *ALK-PROTAC* degrader and inhibits *ALK* activity with an IC₅₀ value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC₅₀ values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .

HY-163807

22-SLF	PROTACs FKBP	Cancer
22-SLF is a PROTAC degrader, that degrades FK506-binding protein 12 (FKBP12) with a DC₅₀ of 0.5 µM in a FBXO22 dependent manner. 22-SLF degrades other endogenous proteins, such as BRD4 and EML4-ALK fusion protein.(Pink: Ligand for target protein SLF (HY-114872); Black: Linker (HY-163821); Blue: Ligand for E3 ligase (HY-163826)) .

HY-160506

PRO-6E	PROTACs c-Met/HGFR Apoptosis	Cancer
PRO-6E is an oral active *PROTAC* based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at 1 μM in MKN-45 cells. PRO-6E inhibits tumor growth in vivo and in vitro. PRO-6E induces cell apoptosis and induces cell arrest (Sturcture Note:(Blue: Cereblon ligand (HY-103596), Black: linker；Pink: ALK/c-Met inhibitor Crizotinib (HY-50878)) .

HY-159147

SIAIS039	PROTACs ROS Kinase Apoptosis	Cancer
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific *PROTAC* with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .

Cat. No.	Product Name		Classification

HY-W040304

Alkynyl Palmitic Acid 1 Publications Verification ALK-C16		PROTAC Synthesis Alkynes
Alkynyl Palmitic Acid (Alk-C16) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs . Alkynyl Palmitic Acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147206D

Biotin-PEG-Alk (MW 5000)		Alkynes PROTAC Synthesis
Biotin-PEG-Alk (MW 5000) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Biotin-PEG-Alk (MW 5000) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159147

SIAIS039		Azide
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific *PROTAC* with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.